# Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

> **NCT01341301** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 25 (actual)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **RADIATION:** Total Body Irradiation
- **BIOLOGICAL:** Donor Lymphocyte Infusion (DLI)
- **DRUG:** Cyclophosphamide
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate mofetil
- **PROCEDURE:** Allogeneic hematopoietic stem cell transplantation
- **OTHER:** Laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01341301
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2013-11-04
- **Final completion:** 2014-08-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01341301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01341301, "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01341301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*